Bank Of America Corp Biovie Inc. Transaction History

Bank Of America Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.4 - $0.56 $5,412 - $7,577	-13,531 Reduced 38.57%	21,553 $8,000
Q1 2024 May 15, 2024	SELL	$0.53 - $1.89 $726 - $2,589	-1,370 Reduced 3.76%	35,084 $18,000
Q4 2023 Feb 14, 2024	BUY	$1.22 - $5.24 $34,290 - $147,280	28,107 Added 336.73%	36,454 $45,000
Q2 2023 Aug 14, 2023	SELL	$4.09 - $8.29 $66,458 - $134,704	-16,249 Reduced 66.06%	8,347 $35,000
Q1 2023 May 12, 2023	BUY	$4.89 - $10.53 $30,014 - $64,633	6,138 Added 33.25%	24,596 $198,000
Q4 2022 Feb 10, 2023	BUY	$3.86 - $42.0 $71,247 - $775,236	18,458 New	18,458 $143,000
Q1 2022 May 16, 2022	BUY	$2.74 - $5.65 $6,028 - $12,430	2,200 New	2,200 $10,000
Q4 2021 Feb 08, 2022	SELL	$4.41 - $6.99 $4,820 - $7,640	-1,093 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.69 - $16.93 $7,312 - $18,504	1,093 New	1,093 $7,000

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $92M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.